Forskning ved Københavns Universitet - Københavns Universitet

Forside

Drug-drug Interactions between Lumefantrine and Commonly-used Antiretroviral Treatment: An Individual Participant Data Population Pharmacokinetic Meta-Analysis

Publikation: Bidrag til tidsskriftTidsskriftartikel

Dokumenter

  • Jose Francis
  • Karen I Barnes
  • Lesley Workman
  • Tamara Kredo
  • Lasse S. Vestergaard
  • Richard M Hoglund
  • Pauline Byakika-Kibwika
  • Mohammed Lamorde
  • Stephen I Walimbwa
  • Ifeyinwa Chijioke-Nwauche
  • Colin J Sutherland
  • Concepta Merry
  • Kimberley K Scarsi
  • Nyagonde Nyagonde
  • Martha M Lemnge
  • Saye H Khoo
  • Sunil Parikh
  • Francesca T Aweeka
  • Joel Tarning
  • Paolo Denti

Treating malaria in HIV co-infected individuals should consider potential drug-drug interactions. Artemether-lumefantrine is the most widely recommended treatment for uncomplicated malaria globally. Lumefantrine is metabolized by CYP3A4, an enzyme that commonly-used antiretrovirals often induce or inhibit. A population pharmacokinetic meta-analysis was conducted using individual participant data from ten studies, with 6,100 lumefantrine concentrations from 793 non-pregnant adult participants (41% HIV-malaria co-infected, 36% malaria-infected, 20% HIV-infected, and 3% healthy volunteers). Lumefantrine exposure increased 3.4-fold with co-administration of lopinavir/ritonavir-based antiretroviral therapy (ART), while it decreased by 47% with efavirenz-based ART and by 59% in the patients with rifampicin-based anti-tuberculosis treatment. Nevirapine- or dolutegravir-based ART and malaria- or HIV-infection were not associated with significant effects. Monte Carlo simulations showed that those on concomitant efavirenz or rifampicin have 49% and 80% probability of day-7 concentrations <200 ng/mL respectively, a threshold associated with an increased risk of treatment failure. The risk of achieving sub-therapeutic concentrations increases with larger body weight. An extended 5-day and 6-day artemether-lumefantrine regimen is predicted to overcome these drug-drug interactions with efavirenz and rifampicin respectively.

OriginalsprogEngelsk
Artikelnummere02394
TidsskriftAntimicrobial Agents and Chemotherapy
Vol/bind64
Udgave nummer5
Antal sider17
ISSN0066-4804
DOI
StatusUdgivet - 2020

Bibliografisk note

Copyright © 2020 Francis et al.

ID: 236602707